Bei Zhou

Otto Berndt Str. 3
Darmstadt, HE 64206, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA study.

Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA study.

Journal: RMD open

Published: October 24, 2025

High-Concentration Alcohol Generation in Bipolar Membrane CO Electrolyzer.

High-Concentration Alcohol Generation in Bipolar Membrane CO Electrolyzer.

Journal: Angewandte Chemie (International ed. in English)

Published: August 08, 2025

Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study.

Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study.

Journal: Annals of the rheumatic diseases

Published: June 02, 2025

Two-Step Procedure to Detect Cosmological Gravitational Wave Backgrounds with Next-Generation Terrestrial Gravitational-Wave Detectors.

Two-Step Procedure to Detect Cosmological Gravitational Wave Backgrounds with Next-Generation Terrestrial Gravitational-Wave Detectors.

Journal: Physical review letters

Published: February 06, 2025

Probing a New Regime of Neutrino Self-Interactions with Astrophysical Neutrinos and the Relativistic Cosmic Neutrino Background.

Probing a New Regime of Neutrino Self-Interactions with Astrophysical Neutrinos and the Relativistic Cosmic Neutrino Background.

Journal: Physical review letters

Published: January 23, 2025

K-Doping Suppresses Oxygen Redox in P2-Na0.67Ni0.11Cu0.22Mn0.67O2 Cathode Materials for Sodium-Ion Batteries.

K-Doping Suppresses Oxygen Redox in P2-Na0.67Ni0.11Cu0.22Mn0.67O2 Cathode Materials for Sodium-Ion Batteries.

Journal: Small (Weinheim an der Bergstrasse, Germany)

Published: April 15, 2024

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.

Journal: RMD open

Published: February 27, 2024

Entropy-Mediated Stable Structural Evolution of Prussian White Cathodes for Long-Life Na-Ion Batteries.

Entropy-Mediated Stable Structural Evolution of Prussian White Cathodes for Long-Life Na-Ion Batteries.

Journal: Angewandte Chemie (International ed. in English)

Published: October 12, 2023

Development of a General and Selective Nanostructured Cobalt Catalyst for the Hydrogenation of Benzofurans, Indoles and Benzothiophenes.

Development of a General and Selective Nanostructured Cobalt Catalyst for the Hydrogenation of Benzofurans, Indoles and Benzothiophenes.

Journal: Angewandte Chemie (International ed. in English)

Published: October 25, 2022

The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.

The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.

Journal: Advances in therapy

Published: May 16, 2022

Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.

Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.

Journal: The Journal of rheumatology

Published: April 20, 2021

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.

Journal: Rheumatology (Oxford, England)

Published: February 20, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026